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Key points:  
 
 Remyelination is a spontaneous regenerative process in the adult mammalian 
central nervous system in which new oligodendrocytes and myelin sheaths are 
generated from a widespread population of adult progenitor cells. 
 
 Remyelination involves the distinct stages of progenitor activation, recruitment 
(proliferation and migration) and differentiation into mature myelin-sheath forming 
oligodendrocytes: each is orchestrated by a complex network of cells and signaling 
molecules. 
 
 The efficiency of remyelination declines progressively with adult aging, a 
phenomenon that has a profound bearing on the natural history chronic 
demyelinating diseases such as multiple sclerosis, although experimental studies 
have revealed that the age-affects are reversible. 
 
 Remyelination is neuroprotective, limiting the axonal degeneration that follows 
demyelination. Restoring remyelination is therefore an important therapeutic goal 
so as prevent neurodegeneration and progressive disability in multiple sclerosis and 
other myelin diseases. 
 
 Insights into the mechanism governing remyelination as well as an increasing 
number of high throughput screening platforms have led to the identification of a 
number of drug targets for the pharmacological enhancement of remyelination, 
some of which have entered clinical trials. 
 
 Advances in the generation of large numbers of human stem and progenitor cells, 
coupled with compelling preclinical data, have opened up new opportunities for cell 
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Abstract | Although the core concept of remyelination — based on the activation, migration, 
proliferation and differentiation of CNS progenitors — has not changed over the past 20 years, 
our understanding of the detailed mechanisms that underlie this process has developed 
considerably. We can now decorate the central events of remyelination with a host of 
pathways, molecules, mediators and cells, revealing a complex and precisely orchestrated 
process. These advances have led to recent drug-based and cell-based clinical trials for myelin 
diseases, and have opened up hitherto unrecognized opportunities for drug-based 





Contrary to the oft-expressed view that the CNS has little capacity for regeneration, injury to 
oligodendrocytes, the myelin-forming cells of the CNS, can be followed by a robust 
regenerative response leading to the formation of new myelin sheaths — a process termed 
remyelination1,2. This regenerative response is most clearly seen in young animals following 
experimental demyelinating lesions, which can be created by a number of techniques (BOX 
1). It is also seen in humans following lesions such as those caused by the demyelinating 
disease multiple sclerosis (MS)3-5. For many patients with this disease, however, 
remyelination ultimately fails and it is thought that the loss of metabolic support normally 
provided by myelin sheaths to axons contributes to the axonal and neural degeneration and 
to the progressive disability that characterise the later stage of MS6,7.  
 
The study of remyelination is important to biologists and clinicians alike, as it provides an 
excellent exemplar of an important and emerging discipline — tissue regeneration. The 
inexorable rise in disability within ageing populations represents one of the major challenges 
for health care in the 21st-century, yet there are no therapies in the clinic that directly address 
this by promoting tissue regeneration — all such treatments simply prevent further damage 
(although in so doing they may allow natural healing events to proceed more efficiently). 
When the endogenous regenerative capacity becomes limited, as in individuals with MS, 
disability inevitably results. What is therefore required is an understanding of tissue 
regeneration — what drives it and why does it fail? 
 
A key question in tissue regeneration is how, against a backdrop of the potentially hostile 
environment of damaged tissue that has attained its full size and complexity, can new cells 
generated from residents stem and progenitor populations integrate and become functional? 
The study of remyelination provides an accessible process to study these issues. It is also a 
very important area of research in its own right; if, as we will argue below, remyelination is 
neuroprotective and can be enhanced in the CNS following diseases characterised by myelin 
loss, such as MS and perinatal white-matter injury, effective therapies for diseases that 
impose an enormous financial burden on society become a realistic goal. 
 
As we stated in our previous reviews in 2002 and 2008, the major challenge for the field 
remains the discovery and delivery into the clinic of drugs that enhance remyelination and 
lessen neurodegeneration1,2. Since 2008, however, there has been a step change in our 
understanding of the cells and the signalling pathways that are responsible for remyelination, 
on a scale that now defies comprehensive coverage in a single review. Here, we review some 
of the advances that have occurred, focusing on how the underlying biology has provided a 
platform for the identification of biologics and small molecules that enhance remyelination 
and are heralding the advent of a new experimental medicine-based era. 
 
[H1] Why is remyelination important? 
CNS myelin has two functions: it provides metabolic support to the axon and allows rapid 
transmission of action potentials along the axon6,8,9. In the former, monocarboxylate 
transporters on the oligodendrocyte enable the transfer of lactate from the glial cell to the 
axon and, in doing so, provide the substrate for axonal ATP production via the citric acid 
cycle10-12. In the latter, nodes of Ranvier form by adhesive interactions between axon and 
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paranodal loops at the end of each sheath, leading to the localisation of voltage-dependent 
sodium channels in the gaps between sheaths, which enables saltatory conduction13,14. The 
rationale for remyelination therapies is therefore that they will both restore metabolic 
support to the axon to prevent the axon degeneration responsible for progressive disability 
and restore the nodes that are required to facilitate conduction and hence function (FIG. 1). 
Below, we examine the experimental evidence supporting these objectives. 
 
[H3] Prevention of neurodegeneration. If remyelination prevents axon degeneration, CNS 
regions in which remyelination is enhanced should show increased numbers of viable axons.  
Indeed, various human and animal neuropathological studies suggest that axonal 
degeneration occurs more in areas of acute and chronic demyelination15 than in areas of 
remyelination16. However, such studies do not show causality — successful remyelination 
might simply reflect the presence of healthy axons that are able to support new myelin 
formation, while remyelination failure might result from axonal damage perturbing any 
physical and biochemical cues required for myelination. The need to consider this alternative 
explanation is highlighted by the evidence for intrinsic axonal defects, such as mitochondrial 
abnormalities, as potential causes of axonal and neuronal degeneration in MS17-19.  
 
Distinguishing cause and effect requires experimentation, and can only be addressed in animal 
models in which the strategy used to prevent or enhance remyelination has no direct effect 
on the axons. Three experimental strategies have been used to address this issue. The first 
has been the transplantation of cells capable of remyelination after administration of the 
oligodendrocyte toxin cuprizone to mice combined with the use of irradiation to prevent 
endogenous remyelination. This approach rescued remyelination and led to a decrease in 
axonal damage20. The second strategy has been the selective genetic ablation of 
oligodendrocytes by the cell-specific expression of diphtheria toxin to induce demyelination 
which resulted in secondary axonal injury, an effect that was still observed even when the 
activation of the adaptive immune system, which could lead to bystander damage of axons, 
was prevented21. The third strategy has involved enhancing remyelination by the removal the 
M1 muscarinic receptor from oligodendrocytes so as to enhance their differentiation. This 
approach showed increased preservation of axons in an experimental autoimmune 
encephalomyelitis (EAE)22. Although these studies do not completely rule out the possibility 
that immunomodulatory effects of progenitors on the microglia or other cells types within the 
lesion may contribute to axonal injury or protection, together they do provide persuasive 
evidence for a direct neuroprotective effect of remyelination. 
 
[H3] Restoration of function. The effectiveness of remyelination in restoring conduction 
velocity is well established. Electrophysiological studies in the rodent spinal cord and 
brainstem showed that remyelination restores rapid and therefore, probably, saltatory 
conduction9. The spontaneous remyelination that occurs in cats following extensive 
demyelination caused by dietary manipulation leads to restoration of function, as measured 
by clinical examination23. However, whether remyelination leads to complete and sustained 
restoration of function will require more sophisticated analyses of neural circuit function and 
remains to be determined24, especially in situations in which a degree of axonal loss has 
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already occurred. Given that remyelination leads to thinner myelin sheaths than myelination 
(see below), it is predicted from computational studies showing that velocities increase with 
myelin thickness that conduction will not completely return to normal25.  
 
There may be other, longer-term effects of remyelination. The traditional view that the myelin 
sheath is fixed structurally after formation has been revised in light of studies showing that 
activation of phosphatidylinositol 3-kinase signalling, optogenetic stimulation of axonal 
activity or enrichment of the social environment can increase the thickness and/or number of 
sheaths26-28. Together, these results show that oligodendrocytes are able to respond to 
axonal and potentially other signals to alter sheath properties. This plasticity has been termed 
adaptive myelination and it raises the question as to whether this also provides a mechanism 
for learning, in which circuits that show sustained activity are reinforced by increased 
myelination. The fascinating question that follows on from these studies is whether the 
sheaths on remyelinated axons also show plasticity and, if not, does this limit any capacity for 
learning and thus contribute to the cognitive dysfunction seen in patients with MS?  
 
An additional, similarly theoretical, concern over complete functional restoration comes from 
studies linking the formation of new oligodendrocytes to learning. Oligodendrocytes are born 
and generate new myelin sheaths throughout life29-31, and an important study showed that 
this new oligodendrocyte differentiation is required for motor learning in adult mice32.  
Although this work did not establish that myelination per se is required for motor learning — 
the newly formed oligodendrocytes required for motor learning could have had other 
beneficial effects on axonal function, such as metabolic support — it did predict that any 
reduction in the number of progenitors in and around remyelinated lesions could have longer-
term effects on learning by limiting this capacity for the generation of new oligodendrocytes. 
Although oligodendrocyte progenitor cell (OPC) numbers return to normal even after 
repeated acute episodes of demyelination–remyelination in rodents33-35, it is possible that 
exposure to a sustained demyelinating stimulus might lead to a depletion of OPC numbers36,37 
and  compromise this intriguing role of oligodendrocytes. 
 
[H1] Mechanisms of remyelination 
The keys stages in remyelination are now well established (FIG. 2). In response to 
demyelinating injury, adult progenitors undergo a change in state often referred to as 
activation, in which at least some of these cells in the vicinity of a lesion re-enter the cell 
cycle38.  This enables progenitors to populate and expand within areas of damage through a 
combination of proliferation and migration; finally, they undergo differentiation, a process 
culminating in the formation of new myelin sheaths39,40. These sheaths are often thinner than 
those formed during development, a characteristic widely used to distinguish areas of 
remyelination from normally myelinated axons41.  Recent years have seen an explosion of 
studies identifying factors, both extrinsic (also described as environmental or non-cell 
autonomous) and intrinsic (cell autonomous) that are involved in each of these distinctive 
phases, of which the timely and seamless transition from one to next is essential for efficient 
remyelination42-47. Next, therefore, we will review some of these recent developments that 
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together have transformed our understanding of the mechanisms of this important 
regenerative process and the reasons for its failure. 
  
[H3] Adult oligodendrocyte progenitor cells.The developmental origin of oligodendrocytes 
was established over thirty years ago. They are derived from a now well-characterised 
population of progenitor cells whose name has gone through numerous iterations. Originally 
described as O-2A cells by Raff and colleagues in the 1980s (on account of their ability to 
generate a glial fibrillary acidic protein-expressing cell resembling an astrocyte in tissue 
culture, as well as oligodendrocytes)48, they have subsequently been called NG2 cells (based 
on their expression of a membrane bound protegogylcan), synantocytes, polydendrocytes, 
oligodendrocyte precursor cells and OPCs49-51. Similar cells that are derived from neonatal 
OPCs (nOPCs) and that persist into adulthood are called adult OPCs (aOPCs)52. These cells 
constitute approximately 6% of the CNS total cell number53 and are abundant throughout the 
CNS, where they generate new oligodendrocytes throughout life. They also receive 
glutamatergic and GABAergic synaptic inputs, and recent studies suggest that they have a 
potentially important role in modulating neuronal circuit activity54-57.  
 
Given the central role of OPCs in developmental myelination, it seemed likely that aOPCs 
would be the cells that are responsible for generating new oligodendrocytes during the 
regenerative process of remyelination. Several lines of evidence strongly supported such a 
view, but it was not until the advent of genetic fate mapping strategies in which marker genes 
could be specifically expressed within aOPCs in such a way that their differentiation fates 
could be followed that the formal evidence that aOPCs are the major source of new 
oligodendrocytes could be confirmed39,40,58 (FIG. 2). More recent studies using dual-colour 
reporter mice that identify the developmental origin of aOPCs have revealed that those of 
dorsal developmental origin undergo enhanced recruitment and differentiation during 
remyelination compared with those of ventral origin, revealing a regenerative heterogeneity 
in aOPCs that is determined by developmental origin59.  
 
Fate-mapping studies have also revealed alternative differentiation fates of aOPCs during 
tissue regeneration. Indeed, they have shown that aOPCs can generate astrocytes (albeit in 
small numbers compared with those generated from existing astrocytes) and, perhaps most 
surprisingly, Schwann cells that contribute to CNS remyelination in certain diseases and 
experimental models (BOX 2)39,59. Thus, aOPCs are self-renewing multipotent cells; on this 
basis, a case can be made for regarding these cells as adult CNS stem cells60. 
 
Although aOPCs constitute the overwhelmingly predominant source of new oligodendrocytes 
when one considers the entire CNS, progenitor populations within the sub-ventricular zone 
(SVZ) may also be able to generate new oligodendrocytes in an area of demyelination located 
near to the SVZ, such as the corpus callosum61-63. A long-standing question is whether pre-
existing mature oligodendrocytes might also be a source of new oligodendrocytes during 
remyelination. Genetic fate mapping shows that this is not the case64. However, pre-existing 
oligodendrocytes are able to increase the number of internodes they generate and thereby 
contribute to remyelination if extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) 
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are artificially activated65. 
 
[H3] Activation of adult oligodendrocyte progenitor cells. Progenitor activation is the term 
used to describe the specific set of changes that occur in aOPCs in response to disruption of 
tissue homeostasis caused by injury. This process is closely associated with the proliferative 
response of aOPCs following tissue injury, but whether it occurs within aOPCs before they 
proliferate or is a feature of newly generated aOPCs is unclear. Early descriptions of activation 
described a change in aOPC morphology that was subsequently linked to the increased 
expression of several genes, many of which are transcription factors47,66,67. More recently, a 
thorough description of the changes in gene expression associated with activation have been 
acquired38. Through the use of reporter mice that enable fluorescence-activated cell sorting-
based isolation of specific populations, it has been possible to generate gene expression 
profiles of aOPCs from intact white matter and from regions of demyelination, and compare 
these profiles with those of nOPCs and mature oligodendrocytes from adult CNS. This study 
revealed that the resting aOPC has an expression profile that more closely resembles a mature 
oligodendrocyte than an nOPC, but following demyelination, aOPCs in their activated state 
‘revert’ to a transcriptome than more closely resembles their developmental forebears. This 
makes intuitive sense, as it is only nOPCs and activated aOPCs that need to prepare 
themselves for generating new oligodendrocytes, the former for myelination and the latter 
for remyelination.  
 
The changes in gene expression associated with activation are clearly necessary for the 
ensuing regenerative process. Two examples provide evidence of the critical importance of 
this initial aOPC event. First, the transcription factor TCF7L2 (also known as TCF4) is only 
expressed in aOPCs following tissue injury (it is undetectable in oligodendrocyte lineage cells 
in normal adult CNS)68. As discussed below, this transcription factor is at the heart of canonical 
WNT signalling and serves to maintain aOPCs in the cell cycle as their numbers increase to 
populate areas of demyelination during the recruitment phase of remyelination. The second 
example is provided by the transcription factor SOX2, which, like TCF7L2, is only expressed in 
aOPCs following tissue damage69. SOX2 appears to function as a master switch, with 
expression associated with an increase in aOPC proliferation and the priming these cells for 
eventual differentiation into myelinating oligodendrocytes.  
 
The precise mechanisms for inducing activation are not known but they probably relate to 
the innate immune response that is triggered by tissue injury. A plausible working 
hypothesis involves the initial detection of the change in tissue integrity by microglia 
(presumably via pattern recognition receptors), the activation of these cells and the 
associated secretion of a battery of cytokines and other signalling molecules. These factors 
rapidly activate astrocytes, which secrete a range of factors leading to a rapid change in the 
signalling milieu of the tissue that is detected by aOPCs, causing their activation. It remains 
to be established how the recently identified heterogeneity in the response of astrocytes to 
CNS damage fits into this model of remyelination70. It is likely that signals emanating from 
the damaged tissue (such as damage-associated molecular patterns) also directly contribute 
to OPC activation. Although the process of remyelination is a regenerative sequela of 
primary demyelination, it seems that aOPC activation is not confined to this very specific 
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form of pathology but occurs in all forms of CNS disturbance, and it is possible that aOPC 
activation might contribute to the resolution of other forms of CNS injury71 through other 
recently discovered biological functions of this cell population, such as the control of 
angiogenesis72. 
 
[H3] Co-ordination of recruitment and differentiation. The next identifiable phase of 
remyelination is recruitment — the colonization of areas of demyelination with sufficient 
aOPCs to generate the number of oligodendrocytes required to restore myelination. Mirroring 
a common mechanism employed in development to regulate cell number, in which a surfeit 
of progenitors is generated and then subsequently pruned to the number of differentiated 
cells required, the initial progenitor response to demyelination is usually far in excess of that 
needed. This is invariably the case in experimental models, although in clinical disease the 
situation is less straightforward since there are, as we will discuss below, certainly instances 
where remyelination failure is associated with too few progenitors73,74. The recruitment of 
aOPCs to and within areas of demyelination depends to a large extent on cell division and also 
on cell migration, albeit this migration probably occurs over relatively short distances75.  
 
An extensive literature now exists on the many factors than control both OPC division and 
migration and although only some of this literature relates to the study of aOPCs in the context 
of demyelination, it is likely than many of the mediators described in developmental and in 
vitro systems will contribute to the complex variety of factors regulating the recruitment 
phase of remyelination. The sources of both mitogens and regulators of migration are many 
and there are few, if any, constituents of a demyelinating lesion that do not contribute factors 
involved in aOPC recruitment. Cells of the innate immune system, be they microglia or 
recruited monocyte-derived macrophages, are a major source of factors that enhance aOPC 
activation, proliferation and migration. Astrocytes, activated by the acute injury, are a further 
source, as are cells of the vasculature and the aOPCs themselves38,76,77. The multiplicity of 
recruitment mediators raises the question of why so many factors are needed and from so 
many distinct sources? It seems likely that there are high levels of redundancy, with different 
factors mediating essentially the same function. However, it may also speak to a precisely 
choreographed sequence of events required for recruitment that we as yet have not fully 
understood. 
 
A particularly important part of this choreography is the pathways that inhibit differentiation. 
These are closely linked to the control of the recruitment phase because preventing cells from 
exiting cell cycle by undergoing differentiation is an important part of establishing sufficient 
numbers of progenitors to ensure successful remyelination78. Two key pathways to have 
emerged as negative regulators of OPC differentiation are the Notch pathway, which in 
developmental myelination prevents differentiation79, and the canonical WNT pathway68. A 
clue to the importance of the WNT pathway was initially provided by the identification of the 
transcription factor TCF2L7 in oligodendrocyte lineage cells in remyelination68. This led to a 
series of studies that have not only yielded a detailed understanding of the WNT pathway in 
controlling the transition from the proliferation phase to the differentiation phase but also 
revealed insights into myelin pathology and opened up exciting possibilities by which 
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remyelination might be therapeutically enhanced80-83.  
 
[H3] Differentiation and the formation of thin myelin sheaths. The recruitment phase is 
followed by the differentiation phase, in which recruited aOPC extend processes around 
demyelinated axons and ultimately invest the axon with a new compacted myelin sheath. It is 
now well established in oligodendrocyte biology that there is an exclusivity between the 
mechanisms governing OPC proliferation and those that control the differentiation of OPCs 
into mature myelin-forming oligodendrocytes: for differentiation to occur, a cell must exit the 
cell cycle84, a transition in which SFMBT2 cluster miRNAs, MYC and E2F1 have key roles85-87. 
When remyelination proceeds smoothly, there is a timely transition from the recruitment to 
the differentiation phase. Dysregulation of the kinetics of this transition plays a large part in 
the declining efficiency of remyelination with age, as we discuss later. However, despite its 
importance, relatively little is known about how this transition occurs, although it clearly 
involves kinases that control cell cycle and cell cycle exit78. One possible mechanism relates 
to cell density, which, when it reaches a certain level, initiates differentiation (conversely, a 
decrease in density such as can occur during demyelination, is a stimulus to induce 
recruitment)88-90. The past few years have seen a considerable expansion in our 
understanding of the mechanisms of differentiation by which an aOPC transitions into a 
myelinating oligodendrocyte, including the identification of key transcription factors such as 
MRF and epigenetic regulators91-95. Not all of this information has been gleaned from models 
of demyelination and remyelination, but that which has is especially interesting as it opens up 
exciting opportunities for small molecule-based therapeutic interventions by which 
remyelination might be enhanced clinically (discussed below).  
 
The last stage of oligodendrocyte differentiation is the formation of a new compacted myelin 
sheath. When myelination occurs during development there is a clear relationship between 
myelin sheath thickness (and length) and axon diameter. However, in remyelination, the new 
myelin sheath thickness and length show little increase with increasing axonal diameter. This 
means that, in remyelination, the myelin sheaths are thinner and shorter than the original 
sheaths generated during development41 (FIG. 3). Although some remodelling of the new 
myelin internode occurs, the original dimensions are only attained for small-diameter fibres96-
98. The relationship between axon diameter and myelin sheath thickness is expressed as the 
g ratio, which is calculated as the fraction of the axon circumference to the axon plus myelin 
sheath circumference. The thin myelin sheaths characteristic of remyelination have a higher 
g ratio than that of the normally myelinated axon and this remains the most reliable way of 
unambiguously identifying remyelination. However, while thin myelin sheaths are easily 
detected when large diameter axons are remyelinated, the situation is less straightforward 
for smaller-diameter axons such as those within the corpus callosum, where the normally 
thinner myelin sheaths mean that the g ratios of remyelinated axons are often unchanged97.  
 
An important question in myelin biology is how the relationship between the thickness and 
length of the myelin sheath and axon size is established in developmental myelination and 
why it should fail during remyelination? In the PNS, expression of neuregulin 1 (NRG1)-type III 
on axons is clearly important: less NRG1 results in thinner myelin sheath with an increased g 
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ratio, whereas more NRG1 results in an thicker myelin sheath with a decreased g ratio99. In 
the CNS overexpression of NRG1 leads to hypermyelination in development. However, mice 
lacking expression of Nrg1 or both Erb3 and Erb4 (which encode NRG1 receptors) undergo 
normal myelination, indicating that NRG1 is not necessary for CNS myelination100 and other 
signals, including the cell-intrinsic mechanisms that enable oligodendrocytes to form sheaths 
on artificial fibres that mimic axons101, must contribute to the establishment of the myelin 
sheath parameters. However, none of the mechansistic insights into the control of myelin 
sheath formation in development shed light on the increased g ratio in remyelination. For 
example, while increased expression of NRG1 increases myelin sheath thickness in 
development it fails to do so during remyelination100. Likewise, activation of the AKT pathway, 
a well-established determinant of myelin sheath thickness in development, does not result in 
thicker myelin sheaths in remyelination102. One hypothesis to explain the discrepancy 
between myelination and remyelination is that whereas oligodendrocytes myelinating during 
development associate with expanding axons that are still acquiring their final length and 
diameter and are able to induce adaptive changes in the myelin sheath, the remyelinating 
oligodendrocyte engages an axon that is comparatively static, having already acquired its final 
size. Thus, the remyelinating oligodendrocyte does not encounter the same dynamic stresses 
and other signals that might drive adaptive changes encountered by the myelinating 
oligodendrocyte103, and remyelination reflects largely the activity of the cell-intrinsic 
mechanisms (FIG. 3). 
 
[H1] Systemic factors and remyelination 
As with regenerative processes, remyelination is profoundly affected by systemic factors. 
Recent studies have emphasized two such factors: the essential role of the immune system 
and the profound impact of ageing on the process. 
 
[H3] Remyelination and the immune system. Various lines of evidence strongly suggest that 
MS is primarily an autoimmune disease104-106. However, the focus on the immunopathogenic 
nature of the maladaptive immune system in this disease has deflected attention from the 
role of the immune system and especially the innate immune system in remyelination. It is a 
well-established tenet of pathology that one of the functions of inflammation is to prepare 
damaged tissue for reparative processes, and it is now abundantly clear that the innate 
immune response to demyelination has important roles in remyelination. In non-immune-
mediated models of demyelination, this innate immune response is mediated by microglia 
and by monocytes recruited from the circulation. Both cell types have the capacity to develop 
into macrophages. Here, we use the term macrophage to refer to cells of both origins, unless 
a distinction is drawn between the two107 .  
 
A correlation between the abundance of debris-filled macrophages and the efficiency of 
remyelination was reported in early studies of remyelination following toxin-induced 
demyelination, in which the inflammatory response is the consequence of demyelination and 
not its cause, as in immune-mediated models of demyelination such as EAE. A causal 
relationship between the macrophage response and remyelination was demonstrated by the 
depletion of the circulating monocytes that give rise to a proportion of the lesion 
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macrophages, which led to remyelination impairment108. Subsequent studies on the nature 
of the beneficial roles of macrophages focused on their ability to clear the myelin debris 
generated during demyelination by phagocytosis, or on the various factors they secrete that 
influence the behaviour of OPCs and their progeny109,110. Myelin contains inhibitors of OPC 
differentiation, which, in the intact CNS, are thought to prevent OPCs undergoing 
differentiation in the absence of an exposed axon, as to do so would probably lead to them 
undergoing apoptosis111-113. Myelin debris generated by demyelination and containing 
inhibitors of OPC differentiation therefore needs to be removed from the extracellular space 
so that it does not interfere with the final differentiation stage of remyelination114-117. This is 
the function of phagocytic macrophages and the efficiency with which they perform this task 
has a major influence on the efficiency of remyelination.  
 
In addition to any phagocytic role, activated macrophages are a source of a wide spectrum of 
secreted signalling molecules that may stimulate remyelination directly or indirectly118. In 
recent years, many macrophage-derived molecules have been identified that have direct 
effects on OPCs (for example, CXCR4119, tumour necrosis factor120, endothelin 2121 and 
activin-A122), and it is likely that others will be identified. Macrophages may also have roles in 
extracellular matrix remodelling and in the metabolic support of axons and oligodendrocytes 
(via the release of lactate and iron, respectively) and the contribution of these roles to the 
regenerative function of macrophages will need to be clarified123. The precise nature of 
macrophage function is determined by the macrophage state, which is often referred to as 
being either ‘classically activated’ or M1, or ‘alternatively activated’ or M2. Although there 
are many caveats to this terminology, not least because it does not accurately reflect the 
multiple and interchangeable states that these cells can adopt, it nevertheless provides useful 
terms of convenience with which to identify distinctive macrophage contributions. The M1 
state is prevalent during the recruitment phase of remyelination whereas the M2 state is 
dominant and instrumental during the differentiation phase122. The timely transition from the 
M1 to the M2 state is critical for rapid and efficient remyelination. Although both resident 
microglia and recruited monocytes can both give rise to macrophages, it is becoming apparent 
that the two populations can have distinctive roles in CNS pathology124. Elucidating their 
distinctive roles, and that of the recently characterized non-parenchymal macrophages of the 
perivascular space and other brain borders125, will be necessary to fully understand the role 
of the innate immune system in remyelination.  
 
The role of the adaptive immune response in remyelination has received relatively little 
attention. Early reports suggested a positive role for T cells in remyelination, as this process 
was impaired in their absence126,127. A more recent study identified a pro-remyelination role 
for regulatory T-cells present in MS lesions that is mediated in part by their expression of 
CCN3128.   
  
[H3] Ageing and remyelination. It is a common feature of regenerative processes that they 
become less efficient with ageing (which is one of the reasons why ageing occurs)129. 
Remyelination is no exception: it undergoes a progressive slowing in rate throughout adult 
life130-132, which may occur more rapidly in white matter than in grey matter, in which 
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remyelination is thought to be more efficient133. As a result of the slowing of remyelination 
rate, demyelinated axons remain exposed for increasingly long periods134. As these axons 
depend on an intact myelin sheath for their survival, delays in remyelination leave axons 
increasingly vulnerable to degeneration22. Axonal loss is irreversible and as the number of 
lost axons accumulates, the degree of permanent clinical deterioration increases. Thus, the 
transition from treatable relapsing–remitting MS to untreatable chronic progressive MS 
probably occurs to a large extent on the age-associated decline in remyelination efficiency 
and the consequent degeneration of demyelinated axons.   
 
Although it is difficult to know for certain at what rate remyelination occurs in people with 
MS, studies of patient cohorts support this hypothesis: individuals with MS reach specific 
levels of disability at around the same age regardless of the initial pattern of disease and the 
age of disease onset, pointing to an underlying age-associated decline in regenerative 
capacity135. Reports that remyelinated plaques can be found in long-lived individuals is not 
evidence against our hypothesis, as it is not possible to know at what age a lesion occurred or 
how long it took to remyelinate4. Rather, both imaging136 and pathology137 studies point to 
a strong age-effect on remyelination efficiency in MS. 
 
There are several possible explanations for why remyelination efficiency declines with ageing. 
One possibility is that the density of aOPCs declines, leaving fewer cells available to be 
mobilized in response to demyelination. However, the available data indicate that there is no 
age-related decline in aOPC density138,139. However, there is evidence that aOPC activation, 
recruitment and differentiation are all impaired with increasing age138,139, and, of these, the 
effects on differentiation are especially rate limiting as increasing aOPC recruitment following 
experimental demyelination in aged mice does not lead to an acceleration in 
remyelination140. This emphasis on the failure of differentiation with ageing in animal models 
mirrors (and may well contribute to) the frequent occurrence of chronic demyelinating lesions 
containing oligodendrocyte lineage cells that have failed to undergo complete 
differentiation141-143.   
 
The ageing process affects both the intrinsic properties of aOPCs and the cells that form the 
extrinsic environment in which remyelination takes place. That intrinsic changes occur with 
ageing aOPCs is well-established, although the details of these changes have not been 
extensively explored, in part because of the technical challenges of growing aOPCs in tissue 
culture144,145. The age-related changes in the remyelination environment are better 
understood, especially the contributions made by innate immune cells. There is not only an 
age-associated delay in the mobilization of the macrophage response but also a decrease in 
the ability of macrophages within lesions to clear myelin debris, which as described above 
contains factors that inhibit OPC differentiation115,146,147, and a delay in the switching of the 
macrophage population from one that is predominantly M1 to one that is predominantly M2, 
a switch that is important for the induction of OPC differentiation122.  
 
An important question is whether ageing-associated effects are reversible. The answer to this 
question is critical in deciding whether to pursue regenerative therapies based on mobilizing 
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the regenerative properties of endogenous stem and progenitor cell populations. A now 
widely used approach to address this question is the experimental procedure of heterochronic 
parabiosis, in which two adult mice of different ages are joined such that they share a common 
circulation148. This approach has been used to show that deficient remyelination in an aged 
mouse can be reversed, thus establishing the important principle that the effects of ageing on 
remyelination are reversible and validating therapeutic approaches based on targeting 
endogenous OPCs even in aged patients147. Such an approach is further validated by the 
enhancement of remyelination efficiency in aged rats using a small-molecule agonist of the 
nuclear hormone receptor retinoic acid receptor RXR149. 
 
[H1] Enhancing remyelination 
Clearly, the key first step in developing therapies that enhance remyelination and, in doing so, 
prevent neurodegeneration is the discovery of experimental strategies that promote or 
accelerate remyelination in relevant animal models. Two broad approaches have been taken: 
the identification of factors that normally inhibit remyelination (blockers of which will 
therefore promote the process) and the identification of those that accelerate the process.  
 
[H3] Inhibitors of remyelination. A range of environmental components inhibit remyelination, 
including the extracellular matrix150-154; these components have been reviewed 
elsewhere155. Here, we focus on two signalling pathways that have received particular 
attention in view of their potential as targets for therapies to enhance remyelination. As 
discussed above, Notch signaling inhibits oligodendrocyte differentiation during 
development. The extent to which this pathway regulates OPC differentiation during 
remyelination is difficult to assess, despite the persistence of components of the pathway 
being implicated in remyelination failure in MS156. The expression of both Notch and Jagged 
in experimentally-induced areas of demyelination that undergo efficient remyelination, make 
it unlikely that their presence alone can account for remyelination block157. However, studies 
using an inducible Cre-lox approach to ablate Notch1 in OPCs following demyelination have 
yielded slightly different results depending on the type of Cre-driver used. In a study using a 
Plp1 promoter, there was no evidence in support of the prediction that ablation of Notch1 in 
progenitors caused premature progenitor differentiation and therefore accelerated 
remyelination, suggesting that Notch signalling is not a major regulator of OPC differentiation 
pathway during remyelination158. However, a subsequent study using the Olig1 promoter, 
which is expressed ay an earlier stage in oligodendrocyte development than Plp1, revealed an 
earlier onset of OPC differentiation, although this did not result in an overall increase in the 
rate of remyelination159. Thus, the canonical Notch pathway, whose activity in demyelinating 
lesions is enhanced by activated astrocyte-derived endothelin-176, seems to be one of the 
pathways that provides negative regulation of OPC differentiation, albeit not a dominant one. 
This may owe in part to competitive activation of non-canonical Notch signalling in OPCs that 
is involved in the induction of OPC differentiation160. An interesting take on the role of Notch 
signalling and differentiation has been provided by a careful examination of brain tissue from 
individuals with MS161: since Notch-intracellular domain (NICD) is not present within the 
nucleus of OPCs present in chronically demyelinated lesions, it is unlikley to be able to activate 
downstream targets of the notch pathway.  
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Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting 
protein 1 (LINGO-1) is a membrane-associated glycoprotein that is selectively expressed in the 
CNS. Originally shown to regulate axon outgrowth by interaction with the Nogo-66 receptor 
(NgR1) complex, it was subsequently also found to inhibit oligodendrocyte differentiation162. 
OPCs treated with small-interfering RNAs generated against LINGO-1, dominant negative 
LINGO-1 or LINGO-Fc led to cultured cells acquiring a more mature morphology. Consistent 
with this observation, LINGO-1 knock out mice exhibit precocious myelination in 
development162, whereas mice exposed to anti-LINGO-1 antibodies exhibit accelerated CNS 
remyelination in the lysolecithin model of demyelination–remyelination163. Thus, it appears 
that LINGO-1 signalling does play a role in controlling the differentiation of OPC during myelin 
regneration.  However, whether this effect in the animal models is via expression of LINGO-1 
on oligodendrocyte lineage cells, for which unambiguous evidence is sparse, or through its 
expression on axons164 is not clear.  
 
Accelerators of remyelination. Recent years have seen the identification of several 
mechanisms by which OPCs in areas of demyelination can be induced to differentiate into 
myelin-sheath-forming oligodendrocytes. Perhaps the most novel of these is the discovery 
that demyelinated axons can be electrically active and form new glutamatergic synapses with 
OPCs present within areas of demyelination, which, through sensing axonal activity via AMPA 
and kainate receptors, cause OPCs to exit the cell cycle and undergo differentiation165-168.  
 
OPC differentiation during remyelination can also be promoted through a class of 
heterodimeric nuclear receptors containing retinoid X-receptor (RXR)-γ149. A role for RXR-γ in 
remyelination was first identified during a transcriptomic screen of recruitment and 
differentiation stages of the remyelination of a well-established toxin-mediated model of 
demyelination, subsequent loss and gain of function studies both in vitro and in vivo revealed 
that receptor activation resulted in induction of progenitor differentiation. RXR-γ is 
promiscuous in its choice of binding partner and several of these partners, such as thyroid 
hormone receptor and peroxisome proliferator-activated receptor-γ, are well-recognised 
regulators of OPC differentiation, whereas others such as liver X receptor that also regulate 
myelination have less well-characterized roles in the process169,170. Recently, vitamin D 
receptor was identified as a key RXR-γ-binding partner in the control of OPC differentiation171, 
revealing a possible role for vitamin D in the regenerative component of demyelinating 
disease, in addition to its well-documented role as a susceptibility factor for MS172. Given the 
multiple potential binding partners of RXR-γ, an as yet unproven model has emerged in which 
RXR-γ switches its principal binding partner as OPCs proceed through distinctive stages of 
progression from dividing cells, to cells that exits cell cycle, initiate differentiation and 
ultimately become myelinating or remyelinating cells.  
 
[H3] Identifying remyelination drugs 
Given our expanding knowledge of the mechanisms of remyelination and the evidence for its 
neuroprotective and functional effects, the development of drug-based therapies for 
enhancing remyelination in MS and other myelin diseases is now a priority for academia and 
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pharma alike. Two broad approaches have been taken to the discovery of small molecule or 
biological leads that target these stages (FIG. 4).   
 
The first of these approaches has been the targeting of specific intrinsic or extrinsic signals 
that regulate the different stages of remyelination. This approach has led to the identification 
of a plethora of potential drugs and targets150,173-187 and to the first human trials of drugs 
designed specifically to enhance remyelination in MS.  Humanized monoclonal antibodies 
against LINGO showed promise in early trials in optic neuritis188 but failed to meet primary 
endpoints in a Phase 2 trial in MS (ClinicalTrials.gov Identifier: NCT01864148). Other 
candidates within these regulatory signals are being explored as targets in pre-clinical studies, 
but here the lack of a single animal model that recapitulates the features of progressive MS 
(as discussed in BOX 1) is a significant impediment. Moreover, it is only when using toxin 
models in aged animals that one can generate lesions that remyelinate so slowly that they 
mimic remyelination failure in MS and also better resemble the age of patients most in need 
of and most likely to benefit from regenerative therapies149. An optimal approach will 
therefore require a combination of models for pre-clinical development of small molecules or 
biologics. Even then, this lack of a single model increases the risk that apparently promising 
leads will fail in clinical trials, in part because studies in such models will fail to address 
important interactions between the inflammatory, regenerative and neurodegenerative 
processes. For example, the use of separate inflammatory and regenerative models makes it 
more difficult to assess the balance between the benefits of profound suppression of disease 
by aggressive immunoablative therapies such as humanised monoclonal antibodies or bone 
marrow transplantation and the risks of losing the alternatively-activated microglial cell 
populations described above and the potential impact on the regenerative response. 
 
A key question for the selection of suitable candidates for pre-clinical work is at what point 
does the remyelination process fail during attempted regeneration in MS? Clearly, a drug 
designed to promote a stage of remyelination that is already occurring efficiently during the 
regenerative process will be less effective than one that targets a blocked stage directly. 
However, it is clear from neuropathological studies that MS lesions are heterogeneous. 
Influential studies over the past two decades have defined different patterns of inflammation 
within MS lesions189, and more recent studies examining the regenerative response reveal 
further heterogeneity, in that 30% of lesions lack sufficient OPCs for remyelination whereas 
in the remainder, sufficient OPCs are present but remyelination fails at the later stages of 
differentiation and/or myelin sheath formation73,190. These studies show immediately that 
treatments targeting oligodendrocyte differentiation would only be effective in 70% of 
lesions, with the remainder requiring treatments that promote progenitor activation and 
migration. If these 70% then have further heterogeneity in terms of the stage at which the 
process of remyelination is blocked, then drugs targeting only one stage of the process will be 
even less effective and combination therapies targeting each specific blocked stage will be 
required. It follows that detailed neuropathological studies of the regenerative process are 
required, with the application of technologies such as single cell RNAseq on post mortem 
human material to better define the cell types and stages of differentiation within lesions 
when informative antibodies are not available. 
 
 17 
The second approach to remyelination-promoting drugs is the use of unbiased high-content 
screens examining oligodendrocyte behaviour in response to libraries of small molecules or 
FDA-approved drugs, with the regenerative activity of the compounds showing positive 
effects confirmed by assays of remyelination 191-194. A number of such screens have been 
performed, using either primary cells or pluripotent stem cell-derived oligodendrocyte 
progenitors (FIG. 4). All bar one of these studies examined oligodendrocyte differentiation as 
an endpoint, as measured by the expression of myelin proteins. The one that did not used an 
ingenious micropillar design to examine the next stage of oligodendrocyte differentiation, the 
formation of sheets of membrane that wrap around 3D shapes — in this case the micropillar 
cones — and thus examined the first steps of myelin sheath formation191. Each of the studies 
has identified compounds that enhance differentiation. For some compounds, such as the 
FDA-approved drugs miconazole and clobetasol, there were no obvious signalling pathways 
responsible, although they appear to activate mitogen-activated protein kinase and 
glucocorticoid receptor signalling, respectively.  For others, however, such as the anti-
muscarinic drugs benzatropine and clemastine, novel pathways regulating oligodendrocyte 
differentiation have been identified and confirmed in experimental studies193,195.  
As these hits are FDA-approved drugs, the progression to clinical trials is facilitated, and one 
trial using clemastine has already been completed (ClinicalTrials.gov Identifier: 
NCT02040298), although the outcome has not been reported yet. The analysis of this and 
other trials will be an important landmark and show clearly that the field has progressed into 
the area of experimental medicine. Thus far, however, the screens used to test FDA-approved 
and other libraries have been predicated on the assumption that oligodendrocyte 
differentiation and/or wrapping is a rate-limiting step for remyelination in MS lesions, and 
that sheath formation and reconstruction of the nodes of Ranvier will follow. Given the highly 
complex structure of the multilamelar sheath and the node, and the evidence already 
available from cell biology studies that reveal novel roles for cytoskeletal actin 
depolymerisation and polarity proteins in sheath formation46,196, this assumption may not be 
justified. Further screens focused on these later stages of remyelination, and on steps prior to 
oligodendrocyte differentiation identified in the neuropathology studies as possible points of 
arrest in the remyelination process, may be required. 
 
[H3] Cell therapies  
An alternative approach to remyelination, but one that is logically appropriate only in those 
lesions in which OPCs are not present, is cell replacement by transplantation. Compelling  
experimental evidence that cell transplantation may restore myelination first came in the 
1980s. Patches of myelination were observed following transplantation of wild-type cells into 
shiverer mutant mice197, which lack normal compacted myelin as a result of a deletion in the 
myelin basic protein gene. Subsequently, transplantation of myelin-forming cells into focal 
demyelinated lesions generated by toxin injection was shown to result in 
remyelination198,199. More recent work has shown that such restoration can be extensive as 
transplanted rodent or human cells can myelinate the entire CNS of shiverer mice200-202.  
 
When considered in the context of MS, however, the problems of transplantation into 
multiple lesions each with a chronic inflammatory and potentially adverse environment 
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become germane. A much easier challenge for cell transplantation would be the 
hypomyelinating leucodystrophies — genetic diseases in which oligodendrocytes fail to form 
normal myelin — and here the spectacular results of the shiverer mice transplantation 
experiments are more clearly relevant to the clinical situation. A transplantation trial using 
human CNS stem cells that have the ability to differentiate into oligodendrocytes has been 
performed in children with a severe conatal form of one of these leucodystrophies, Pelizaeus–
Merzbacher disease, caused by a mutation in PLP1203. Although no adverse effects were 
reported in the four children, MRI suggested that only of a modest degree of myelination had 
occurred near to the injection site. Two factors may have contributed to the degree of 
myelination observed compared with that seen in the rodent studies. First, the degree of 
migration of the transplanted cells may be limited, with the major differences in size between 
the rodent and human brain therefore becoming a limiting factor.  Second, the cell 
populations used in the clinical trial were, inevitably given the need to perform prolonged 
testing so as to generate good manufacturing practices-grade cells and a satisfactory safety 
profile, generated using protocols no longer regarded as state-of-the-art by stem cell 
biologists interested in creating oligodendrocytes. They were therefore likely less efficient at 
generating myelin-forming oligodendrocytes than the primary fetal or pluripotent based 
populations used in the shiverer mice studies. 
 
This trial illustrates the scale of the challenge for cell therapies to promote remyelination, and 
it seems premature to consider transplantation in MS without first establishing efficacy in the 
much more propitious environment of the developing brain. For this, the numbers of patients 
suitable for transplantation will probably be small and it will be important to consider other 
conditions in which myelination is prevented owing to oligodendrocyte defects, such as 
radiation-induced or chemotherapy-induced oligodendrocyte progenitor depletion and 
white-matter damage in children being treated for tumours204,205. An additional challenge is 
provided by cell availability. The use of primary fetal cells will be extremely limited owing to 
their availability, making anything more than proof-of-principle studies difficult. Induced 
pluripotent stem cells differentiated into oligodendrocytes and their progenitors provide an 
attractive alternative as this would overcome the need for immunosuppression, but their 
safety remains unproven and many lines generate tumours post transplantation206. 
Embryonic stem (ES) cell-derived oligodendrocytes will probably be the cell of choice, with 
robust differentiation protocols in place207 and with an ongoing clinical trial using ES cell-
derived retinal pigment epithelial cells providing the important proof of principle that ES-cell 
based therapies will meet regulatory standards of safety. 
 
[H3] The future — experimental medicines 
Key milestones for the field will be the early phase clinical trials that demonstrate efficacy of 
a drug or a cell in promoting remyelination. These will, by enabling subsequent cell-based and 
animal-based studies to be designed around questions raised from studies of the trial 
participants, herald the arrival of a genuinely iterative experimental medicine approach to 
remyelination. There are, however, as discussed in BOX 3, major challenges for these trials in 
the development of outcome measures that are sufficiently sensitive to detect the 
regenerative effects of the drug under trial and, equally importantly, ensure that a positive 
effect is not missed. Overcoming these challenges will require the further development of 
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biomarkers for regeneration, and this must now be a major goal for the field. Once these are 
in place we predict that this ‘bench-to-bedside-to-bench-again’ approach will lead to 
genuinely effective regenerative therapies that complement the immunomodulatory drugs 




Box 1 | Experimental models of remyelination 
Experimental models can be ‘disease models’ that provide as close a facsimile of the naturally 
occurring disease, or they can ‘mechanisms models’ that are more reductionist, allowing 
focused analysis of a specific aspect of a complex pathology. Experimental autoimmune 
encephalomyelitis (EAE), in its many guises, is commonly thought to provide a disease model 
of multiple sclerosis (MS). This is however incorrect - although EAE can be induced in a focal 
manner131,208, mimicking an acute MS lesion, and can develop into a chronic inflammatory 
state in some rodent genetic backgrounds, it does not recreate the combination of acute and 
chronic inflammation, regeneration and neurodegeneration that characterizes progressive 
MS. There are in fact no disease models for MS, and it is more correct to think of EAE as a 
mechanisms model for the immunopathogenesis of MS, and not as a model that lends itself 
to the study of the neurobiological aspects of the disease, including remyelination. Instead, 
this requires other mechanisms models. These generally involve the use of toxins that kill 
oligodendrocytes (hence leading to primary demyelination, the substrate for remyelination) 
and, to varying degrees, other cells types. The models commonly in use involve i) injection of 
lysolecithin into the spinal cord or corpus callosum white matter in mice or rats, ii) injection 
of ethidium bromide into cerebellar peduncles in rats or into the spinal cord in rats or mice, 
or iii) oral administration of cuprizone in mice. In each of these models (albeit to a lesser 
extent in the cuprizone model), the site of demyelination is anatomically defined and the 
process of demyelination is temporally separated from the subsequent process of 
remyelination, allowing the latter to be specifically studied without the complication of 
ongoing demyelination. These mechanisms models therefore allow the fundamental biology 
of remyelination to be elucidated without the confounding and complicating involvement of 
an autoimmune process. They, like EAE, do not provide a facsimile of MS. Nevertheless, they 
are of great value as the fundamental mechanisms of remyelination will be applicable to all 
forms of demyelination regardless of how it is induced, be it toxin or immune mediated. This 
is consistent with a general concept in regenerative biology that the mechanism of 
regeneration is independent of the mechanism by which injury occurs.   




Box 2 | Schwann cell remyelination in the CNS 
 
CNS remyelination can sometimes be mediated by Schwann cells as well as by 
oligodendrocytes. This unusual phenomenon occurs in a number of pathological conditions 
including multiple sclerosis, genetic disorders of myelination and traumatic spinal cord injury, 
and can be reproduced in a variety of in vivo experimental models. For many years it was 
assumed that Schwann cells remyelinating CNS axons were derived from PNS sources, and 
that they responded to recruitment signals generated by demyelination and migrated from 
these PNS sources into the CNS. This seemed a very plausible explanation given, first, the 
frequent anatomical distribution of CNS Schwann cells, often close to likely PNS sources such 
as spinal roots, and, second, that CNS Schwann cells occur in CNS regions that are deficient in 
astrocytes, suggesting that a breach in the astrocytic glia limitans of the CNS presents an 
opportunity for peripherally derived Schwann cells to ‘flood’ into CNS territories. However, 
genetic fate-mapping studies have revealed that although some CNS remyelinating Schwann 
cells are of PNS origin, the majority are derived from CNS progenitors. Several key questions 
remain regarding the phenomenon of CNS progenitor-mediated Schwann cell remyelination 
of the CNS. First, are CNS-derived Schwann cells the same as neural crest-derived Schwann 
cells of the PNS? Second, how do adult CNS progenitors become Schwann cells? Third, does it 
make any difference if a CNS axon is myelinated by an oligodendrocyte or a Schwann cell? 
Fourth, if it makes no difference, would strategies to prevent or promote remyelination by 




Box 3 | Designing clinical trials and developing outcome measures 
 
The trial design required to demonstrate the efficacy for any regenerative therapy in multiple 
sclerosis (MS) is complicated by the difficult question of outcome measures. Unlike tissues 
such as skin and liver, the brain cannot be tested by biopsy, so indirect measures of the 
efficacy of regenerative medicines are required. For remyelination, these measures currently 
comprise clinical assessment, imaging and electrophysiology, with each having its 
disadvantages. The clinical phenotype reflects a combination of inflammation, 
neurodegeneration and regeneration, so it is relatively insensitive to remyelination alone. MRI 
has revolutionised our ability to detect inflammatory lesions in MS, but imaging remyelination 
remains challenging203,209,210. Experimental and correlative neuropathological studies have 
suggested that the magnetisation transfer ratio (MTR) is sensitive to remyelination, and the 
wider availability of 7T scanners may also improve our ability to detect regeneration211-213. 
Another imaging strategy, positron emission tomography (PET) to detect a radiolabelled 
compound that incorporates into myelin, may also provide an approach to quantifying 
remyelination, with promising results from a study in MS patients in which enhanced signals 
within lesions correlates with a reduction in disability214,215. Further studies of all three are in 
progress. Electrophysiological techniques such as visual evoked potentials to measure 
conduction velocities represents a logical strategy to show remyelination as this would detect 
the reappearance of fast conduction velocities that are predicted to follow the restoration of 
salutatory conduction188,216,217.  However, the sensitivity and specificity of this technique, in 
which the degree of variation can be considerable, remains to be determined. Also, the 
experimental data from spinal cord showing that the myelin sheaths formed by new 
(remyelinating) oligodendrocytes do not reach normal lengths until months after their 
formation raises the possibility that conduction velocities increase equally slowly and that trial 
protocols need to be prolonged appropriately. 
These concerns over outcome measures are important when one considers that the likely 
effect size in early trials will be small, and are amplified by the issue of lesion heterogeneity 
(see main text). There are at present no clinical investigations that will distinguish lesions 
containing or lacking sufficient oligodendrocytes for myelination. Without the ability to 
separate these lesions, the power of trials for regenerative medicines targeted either at 
promoting progenitor migration or oligodendrocyte differentiation will be greatly diminished 
by the confounding effect of patients within the trial groups for whom the treatment under 
examination would never have any beneficial effect. The danger is therefore that a genuinely 
positive result that could guide further experimental work will be missed not because it did 
not work but because the effect could not be detected, resulting in a treatment strategy being 
abandoned permanently and prematurely. There is therefore an urgent need for strategies, 
most likely in our view to be PET, that enable reliable quantification of lesion heterogeneity 
and remyelination within and between individuals with MS. With such a technology both a 
rational stratification of patient cohorts and an accurate measurement of effect could be 
achieved, allowing selection of those patients most appropriate for any specific experimental 
medicine trial of a regenerative therapy and confident detection of any benefit.  
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Figure 1 | The logic of promoting remyelination. Following demyelination, which in the 
autoimmune disease multiple sclerosis is consequent to the pathological activation of T cells 
and macrophages, the myelin sheath is lost but the underlying axon remains intact. This 
enables the naturally occurring regenerative response of remyelination to generate new 
sheaths from newly formed oligodendrocytes.  Existing oligodendrocytes whose sheaths have 
been damaged do not contribute to the regenerative process.  In the absence of 
remyelination, energy efficient conduction cannot be restored and the supportive role of the 
myelin is lost. This leads to energy deficiency, perturbed axonal transport (as illustrated by the 
accumulation of mitochondria at the node) and ultimately axonal degeneration.  This 
degeneration can trigger a secondary inflammatory response, as illustrated by the presence 
of activated macrophages around the degenerating axon. 
 
Figure 2 |  The biology of remyelination.  a | Following damage to myelinated areas in the 
CNS (illustrated in the upper left panel by a representation of a coronal section through a 
human brain affected by multiple sclerosis). remyelination is initiated by activation of 
oligodendrocyte progenitor cells (OPCs; upper right panel).  These become activated (as 
represented by the colour change), divide and form new oligodendrocytes.  Both progenitor 
cells within and around the lesion can contribute, with the latter migrating into the lesion 
after activation as shown on the right side of the panel.  Note the presence of macrophages 
in the lesion; as discussed in the main text, macrophages play essential roles in the 
phagocytosis of myelin debris and the promotion of the regenerative response.  Following 
oligodendrocyte differentiation, myelin formation proceeds in three steps as shown in the 
sequence illustrated in the lower panel: the formation of multiple processes and the 
expression of myelin proteins such as myelin basic protein, the initial wrapping of the axon by 
an elaboration of myelin membrane and, finally, the formation of multi-layered and 
compacted sheaths by the continued elaboration of membrane, further wrapping of the axon 
and extrusion of the cytoplasm. b | Genetic fate mapping studies, in which fluorescent marker 
proteins are expressed exclusively within adult progenitors, have revealed how these cells 
give rise to new remyelinating oligodendrocytes. The left-hand panel shows a cross section 
from an adult mouse spinal cord in which many of the OPCs are green. These cells are 
especially concentrated in focal areas of demyelination induced 6 days previously by injection 
of lysolecithin into the left ventral white matter (dotted line), indicative of the recruitment 
phase of remyelination. The right-hand panel shows a similar lesion 21 days after lesion 
induction when all of the demyelinated axons are fully remyelinated. The white arrows 
indicate new myelin sheaths expressing myelin proteolipid protein (red), which have been 
made by the green OPCs that have differentiated into myelin-forming oligodendrocytes (from 
REF 39).    
 
Figure 3 | The architecture of remyelination.  a | The sheaths formed by remyelination 
are frequently thinner than those around axons myelinated during development. A 
hypothetical model to explain this characteristic feature of remyelination is illustrated in 
the upper panel.  Studies showing that oligodendrocytes can form sheaths around 
artificial fibers of diameters equivalent to axons reveal the existence of an intrinsic 
pathway requiring only an appropriate shape to form a sheath (upper left panel).  Myelin 
plasticity triggered by activity and changes in axonal diameter (so called adaptive 
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myelination) then results in the elaboration of further myelin membrane, leading to 
thickening and lengthening of the sheath.  After this sheath is lost by disease in the adult 
CNS, when the axon shape is no longer changing (lower right panel) it is the intrinsic 
pathway in the newly-formed oligodendrocyte that is responsible for remyelination – as 
a result the sheath is thinner than those present around unaffected axons (lower left 
panel).  b | Electronmicrograph of myelinated and remyelinated axons following ethidium 
bromide-induced demyelination the deep cerebellar white matter of an adult rat. The 
myelin sheath thickness of the myelinated axons (M1 and M2) is proportional to the axon 
diameter. The remyelinated axons can be recognised by the relatively thin myelin sheaths 
R1 and R2), which are uniformly thin regardless of the axon diameter. Thus, remyelination 
is readily identified in larger diameter axons, while for small-diameter axons myelinated 
and remyelinated becomes difficult to distinguish. c | The g ratio is used to quantify the 
relationship between the axon diameter (x) and the myelinated axon (y): the thinner the 
myelin sheath, the higher the g ratio, and hence remyelinated axons have g ratios that are 
higher than those of myelinated axons (with the exception of the small diameter axons). 
d | In developmental myelination, there is an increase in myelin sheath thickness with 
increasing diameter of axons. In remyelination, however, the myelin sheath thickness 
remains the same regardless of the diameter (see R1 with R2 in part b). (B-D are adapted 
from figures in REF 218). 
 
Figure 4 | Drug discovery for remyelination.  The different steps of oligodendrocyte 
formation and differentiation that might be targeted are shown in the top panel, with 
progenitor cells on the left and myelinating oligodendrocytes on the right.  A number of 
screens of FDA-approved drugs have been performed, which have revealed a number of 
drugs such as those listed here that are potential remyelination medicines. These screens 
have targeted the oligodendrocyte differentiation step or, in one case, the process of 
initial wrapping using micropillars, as illustrated.  None of these screening platforms have 
to date targeted the final critical stage of myelin sheath formation, and it remains 
unknown whether additional signals will be required for this process or whether 






G ratio: this term describes the ratio of the axon circumference to the circumference of the 
myelinated axon and is used to provide a quantitative measure of the myelin sheath thickness 
compared to the axon diameter: in remyelination the g ratio is usually increased. 
 
Demyelination: This is the pathological process in which myelin sheaths are lost form axons 
that remain intact. It is sometimes called primary demyelination to distinguish it from loss of 
myelin that is secondary to axonal loss, which is more accurately called Wallerian 
degeneration and should not be called demyelination. 
 
Remyelination: This is the regenerative process involving the generation of new 
oligodendrocytes from CNS resident progenitor cells and their reinvestment of new myelin 
sheaths around the demyelinated axon. 
 
Oligodendrocyte: This is the cell that makes myelin in the central nervous system. A single 
oligodendrocyte can make up to 80 separate myelin sheaths, although around 10-20 is a more 
usual number. 
 
Schwann cell: This is the cell that make myelin in the peripheral nervous system. A single 
Schwann cell only ever makes a single myelin sheath. In certain circumstances, Schwann cells 
can remyelinate demyelinated axons in the central nervous system. 
 
Multiple Sclerosis: This is a common autoimmune-mediated disease of the central nervous 
system characterised by multiple acute inflammatory foci involving immune-mediated 
demyelination which can undergo spontaneous remyelination but with disease progression 
this becomes less efficient leaving axons chronically demyelinated and prone to irreversible 
degeneration. 
 
Leucodystrophies: These are a family of genetic disease usually characterised by inadequate 
myelination or demyelination. 
 
